The combination delated progression or death compared to Avastin and chemotherapy alone, according to Roche, the manufacturer of the anti–PD-L1 and anti–VEGF agents. Adding Tecentriq (atezolizumab) to ...
NEW YORK, February 03, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313 met its primary endpoint, demonstrating significant improvement in progression-free survival (PFS) at ...
ALAMEDA, Calif. & PARIS--(BUSINESS WIRE)-- Regulatory News: Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial ...
Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC DUBLIN, Oct. 15, 2024 /PRNewswire/ -- Jazz ...
“The significant progression-free survival (PFS) benefit observed with Sarclisa combination therapy compared to VRd is important and encouraging for patients with newly diagnosed multiple myeloma.
The 10-month progression free survival rate was 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone. "These findings ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback